ATE493115T1 - Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum - Google Patents

Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum

Info

Publication number
ATE493115T1
ATE493115T1 AT03751860T AT03751860T ATE493115T1 AT E493115 T1 ATE493115 T1 AT E493115T1 AT 03751860 T AT03751860 T AT 03751860T AT 03751860 T AT03751860 T AT 03751860T AT E493115 T1 ATE493115 T1 AT E493115T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
opioid analgesic
coating
active agent
Prior art date
Application number
AT03751860T
Other languages
English (en)
Inventor
Benjamin Oshlack
Hua-Pin Huang
Rampurna Gullapalli
Meredith Machonis
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE493115T1 publication Critical patent/ATE493115T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
AT03751860T 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum ATE493115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40371102P 2002-08-15 2002-08-15
PCT/US2003/025601 WO2005007135A1 (en) 2002-08-15 2003-08-15 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE493115T1 true ATE493115T1 (de) 2011-01-15

Family

ID=34078931

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07121574T ATE491439T1 (de) 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend einen opioidantagonisten
AT03751860T ATE493115T1 (de) 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07121574T ATE491439T1 (de) 2002-08-15 2003-08-15 Pharmazeutische zusammensetzungen enthaltend einen opioidantagonisten

Country Status (19)

Country Link
US (2) US20050266072A1 (de)
EP (2) EP1542658B1 (de)
JP (1) JP4790415B2 (de)
KR (1) KR20050086409A (de)
CN (1) CN1674873A (de)
AT (2) ATE491439T1 (de)
BR (1) BR0313627A (de)
CA (1) CA2495564A1 (de)
CY (2) CY1111825T1 (de)
DE (2) DE60335426D1 (de)
DK (2) DK1542658T3 (de)
ES (2) ES2358896T3 (de)
HK (1) HK1088211A1 (de)
IL (1) IL166561A0 (de)
MX (1) MXPA05001826A (de)
NZ (1) NZ537763A (de)
PT (2) PT1542658E (de)
SI (2) SI1894562T1 (de)
WO (1) WO2005007135A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
SI2517710T1 (sl) 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
KR101167465B1 (ko) 2000-10-30 2012-07-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
WO2006119389A2 (en) * 2005-05-03 2006-11-09 Mutual Pharmaceutical Company, Inc. Quinine-containing controlled-release formulations
US20070077313A1 (en) * 2005-10-04 2007-04-05 U.S. Pharmaceutical Corporation Toleration iron supplement compositions
FR2894143B1 (fr) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
US20080119501A1 (en) * 2006-04-28 2008-05-22 Hein William A Immediate release oxymorphone compositions and methods of using same
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
DK2719378T3 (en) * 2006-06-19 2016-10-17 Alpharma Pharmaceuticals Llc pharmaceutical compositions
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
DK2046300T3 (da) * 2006-08-04 2010-07-26 Ethypharm Sa Oralt desintegrerende multilagstablet
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
CA2923102C (en) * 2007-08-13 2019-10-15 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
CA2749273C (en) * 2008-01-09 2018-09-04 Charleston Laboratories, Inc. Pharmaceutical oral dosage form comprising a triptan and an antiemetic
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク． メトプロロールを含むアルコール耐性持続放出性経口剤形
WO2014146093A2 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
EP3423041A4 (de) * 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
CN111836618A (zh) * 2018-02-08 2020-10-27 景凱生物科技股份有限公司 类阿片受体拮抗剂的固体剂型用的医药剂型
EP4225312A1 (de) * 2020-10-06 2023-08-16 Scilex Holding Company Orale verzögerte burst-formulierung von niedrigdosiertem naltrexon oder naloxon zur behandlung von fibromyalgie und langer covid
EP4176724A1 (de) 2021-11-09 2023-05-10 Universität Hohenheim Verwendung eines oleogels als eine schicht oder beschichtung

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916889A (en) 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
GB9407386D0 (en) * 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
JPH11505547A (ja) * 1996-03-13 1999-05-21 エール ユニバーシティ ナルトレキソン及び関連化合物を用いる禁煙処置
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6120806A (en) * 1997-06-25 2000-09-19 Whitmire; David R. Oral formulations for controlled release of alcohol deterrents
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
RU2241458C2 (ru) * 1997-12-22 2004-12-10 Эро-Селтик, С.А. Комбинации агонист/антагонист опиоида
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6765010B2 (en) * 1999-05-06 2004-07-20 Pain Therapeutics, Inc. Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2517710T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
WO2001085257A2 (en) * 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
DE20220910U1 (de) * 2001-08-06 2004-08-05 Euro-Celtique S.A. Zusammensetzungen zur Verhinderung des Missbrauchs von Opioiden
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
MXPA04001210A (es) * 2001-08-06 2004-07-08 Euro Celtique Sa Formulaciones de agonista opioide con antagonista liberable y aislado.
CN1652752A (zh) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US20040192715A1 (en) * 2003-02-05 2004-09-30 Mark Chasin Methods of administering opioid antagonists and compositions thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products

Also Published As

Publication number Publication date
ATE491439T1 (de) 2011-01-15
PT1894562E (pt) 2011-01-14
HK1088211A1 (en) 2006-11-03
US20050266072A1 (en) 2005-12-01
DE60335426D1 (de) 2011-01-27
EP1894562A1 (de) 2008-03-05
NZ537763A (en) 2006-08-31
IL166561A0 (en) 2006-01-15
MXPA05001826A (es) 2005-04-19
CN1674873A (zh) 2005-09-28
EP1542658A1 (de) 2005-06-22
DK1894562T3 (da) 2011-03-28
SI1542658T1 (sl) 2011-04-29
EP1542658B1 (de) 2010-12-29
SI1894562T1 (sl) 2011-04-29
ES2358151T3 (es) 2011-05-06
KR20050086409A (ko) 2005-08-30
BR0313627A (pt) 2005-06-21
JP4790415B2 (ja) 2011-10-12
CA2495564A1 (en) 2005-01-27
DK1542658T3 (da) 2011-04-04
ES2358896T3 (es) 2011-05-16
DE60335557D1 (de) 2011-02-10
EP1542658A4 (de) 2006-04-05
WO2005007135A1 (en) 2005-01-27
EP1894562B1 (de) 2010-12-15
JP2006514988A (ja) 2006-05-18
CY1111825T1 (el) 2015-10-07
US20160317456A1 (en) 2016-11-03
CY1111821T1 (el) 2015-10-07
PT1542658E (pt) 2011-02-03

Similar Documents

Publication Publication Date Title
ATE493115T1 (de) Pharmazeutische zusammensetzungen enthaltend ein opioidanalgetikum
ATE345112T1 (de) Opioid enthaltende arzneiform gegen missbrauch
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
PT1183014E (pt) Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
DE60316552D1 (de) Tablette mit hohem wirkstoffgehalt
ATE320799T1 (de) Retardierte, orale, pharmazeutische darreichnungsformen mit tramadol
DK1545662T3 (da) Lægemiddelindgivelsessystem
EA200501586A1 (ru) Фармацевтические продукты
DK1473003T3 (da) Lægemiddeladministrationsanordning
ATE526973T1 (de) Verbesserte arzneimittelabgabe in transdermalen systemen
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
ATE460169T1 (de) Pharmazeutische formulierung mit lanthanum- verbindungen
ATE460942T1 (de) Exendine zur glucagon suppression
DE69904312T2 (de) Pharmazeutische aerosolformulierung
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
AU2003245774A1 (en) Pharmaceutical dosage form bearing pregnancy-friendly indicia
WO2001089527A3 (en) Pharmaceutical composition comprising loratadine and a nasal decongestant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1542658

Country of ref document: EP